Takeda Pharmaceuticals manufactures the oral tablet known as Uloric, which is prescribed to treat hyperuricemia, a disorder marked by increased levels of uric acid in the body. Uloric is frequently used to treat gout over the long term. It works by preventing the enzyme xanthine oxidase from acting, which lowers uric acid levels. But because of serious adverse effects like liver damage, heart attacks, and strokes, the medication has come under scrutiny.
The Food and Drug Administration (FDA) reassessed Uloric's safety profile in light of alarming evidence. The medication may raise the chance of death, according to research that was discovered after the CARES clinical study was published in the New England Journal of Medicine in March 2018. As a result, the FDA limited Uloric's recommendation to a second-line gout medication that would only be given to patients who were unable to take allopurinol or did not respond well to it.
A growing number of legal actions have been brought against Takeda Pharmaceuticals, mainly because of the drug's increased risk of death. Plaintiffs are bringing lawsuits claiming that there have been other serious health effects, such as deep vein thrombosis, pulmonary embolisms, and strokes. These personal injury claims could develop into class-action lawsuits that attempt to provide victims and their families with significant financial compensation.
You could be able to take part in the Uloric lawsuit, if you or a family member was prescribed Uloric and later experienced major adverse effects, such as cardiovascular problems. Seeking advice from your medical records is essential before pursuing any legal action. These records might be used as crucial proof of how the medication adversely affected your health. To find out more about the current legal proceedings concerning Uloric, please visit our website at medlegal360.
This instance serves as a reminder of the significance of careful drug screening and continuous clinical research to reassess the safety of drugs, even after they have been put on the market.
